ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Aspen To Acquire Merck Business

by Ann M. Thayer
July 1, 2013 | APPEARED IN VOLUME 91, ISSUE 26

South Africa’s Aspen Group is acquiring an active pharmaceutical ingredients business and the option to buy 11 finished products from Merck & Co. With 2012 sales of $370 million, the API business includes manufacturing plants in the Netherlands, a facility in Iowa, and an Illinois sales office. Aspen will pay about $47 million for the business and $390 million for existing inventory. The deal also includes a 10-year agreement to supply APIs to Merck. Aspen could pay another $600 million for the 11 products, which span several therapeutic areas and netted $248 million in sales last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment